<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04209127</url>
  </required_header>
  <id_info>
    <org_study_id>ADENOMIC1</org_study_id>
    <nct_id>NCT04209127</nct_id>
  </id_info>
  <brief_title>Comparing Efficacy of Microwave vs Embolization Treatment for Adenomyosis</brief_title>
  <acronym>ADENOMIC</acronym>
  <official_title>Single Blinded Randomized Controlled Study of Symptom Improvement After Uterine Artery Embolization (UAE) Versus Ultrasound Guided Percutaneous/Transvaginal Microwave Ablation, Evaluated by Validated Questionnaires</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Karolinska Institutet</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Karolinska Institutet</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Single blinded randomized controlled study of symptom improvement after uterine artery&#xD;
      embolization (UAE) versus ultrasound guided percutaneous/transvaginal microwave ablation,&#xD;
      evaluated by validated questionnaires.&#xD;
&#xD;
      Adenomyosis is a benign condition causing pain and bleeding disorders in many women.&#xD;
      Hysterectomy has historically been the golden standard for treatment as well as&#xD;
      (postoperatively) diagnosis of the disease. In accordance with refined diagnostic tools such&#xD;
      as ultrasound and/or MRI, minimally invasive treatments for adenomyosis are being explored.&#xD;
&#xD;
      We plan to compare two minimally invasive techniques: embolization of the uterine artery (a&#xD;
      commonly used procedure) and microwave ablation of adenomyotic tissue (previously only in&#xD;
      clinical use in China).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Single blinded randomized controlled study of symptom improvement after uterine artery&#xD;
      embolization (UAE) versus ultrasound guided percutaneous/transvaginal microwave ablation,&#xD;
      evaluated by validated questionnaires.&#xD;
&#xD;
      Background&#xD;
&#xD;
      Adenomyosis is a benign gynecological condition, where endometrial glands and stroma invades&#xD;
      the myometrial walls of the uterus. The disease is thought to be estrogen-dependent, but the&#xD;
      etiology, as well as the prevalence, is currently unknown. Known risk-factors are previous&#xD;
      uterine surgery and parity, although the disease has been found also in nulligravida with no&#xD;
      previous uterine trauma. Adenomyosis can cause severe dysmenorrhea, menorrhagia, chronic&#xD;
      pelvic pain and infertility. Historically diagnosis has been made post hysterectomy by&#xD;
      pathologists, however with transvaginal ultrasound (TVUS) as well as MRI the condition is now&#xD;
      possible to identify with non-invasive methods.&#xD;
&#xD;
      Hysterectomy has previously been seen as the golden standard treatment for adenomyosis, but&#xD;
      may cause long-term side effects such as genitovaginal prolapse. It also carries a&#xD;
      substantial risk of short term complications such as infections and organ damage.&#xD;
&#xD;
      Symptomatic treatment such as the levonogestrel intrauterine system (LNG-IUS) can be&#xD;
      effective, however there is a risk of expulsion and irregular bleedings.&#xD;
&#xD;
      In recent years, increasing attention has been paid to the study of minimally invasive or&#xD;
      non-invasive therapies with uterine preservation such as uterine arterial embolization (UAE),&#xD;
      radiofrequency (RF), microwave treatment and high intensity focused ultrasound (HIFU). A&#xD;
      randomized controlled study is ongoing, comparing UAE and hysterectomy. RF ablation often&#xD;
      requires the aid of a laparoscopic procedure, which is invasive. HIFU is currently only&#xD;
      described in small cohorts and case-reports. Ultrasound or computer tomography guided&#xD;
      percutaneous microwave thermal ablation is minimally invasive, has low time requirements, is&#xD;
      easy to perform, and has been broadly used for the treatment of solid tumours in organs other&#xD;
      than the uterus with favourable effects.&#xD;
&#xD;
      Microwave ablation of adenomyosis has been performed in China. The effect and acceptability&#xD;
      has been high. The research team in this study has been to China to study the treatment. We&#xD;
      have visited the clinic and studied the procedure as well as talked to patients pre- and post&#xD;
      operatively . The equipment at Danderyd Hospital has the same output effects as the equipment&#xD;
      in China. Danderyd Hospital has approved the method for use in uterine myomas. However, no&#xD;
      randomized comparative study of other minimally invasive methods has been performed.&#xD;
&#xD;
      This study aims to compare the effectiveness, feasibility and acceptability of percutaneous&#xD;
      CT- or ultrasound guided microwave ablation and uterine artery embolization for the treatment&#xD;
      of adenomyosis in a randomized single blind study.&#xD;
&#xD;
      Recruitment and Randomization&#xD;
&#xD;
      Women fulfilling inclusion criteria and without exclusion criteria will be identified at the&#xD;
      outpatient clinic of Danderyd Hospital. Advertisement may be placed in local newspapers or on&#xD;
      social media (Facebook and Instagram) and relevant webpages or in gynecological clinics.&#xD;
&#xD;
      Women will be randomized after having been informed orally and in written and after having&#xD;
      signed informed consent and after fulfilling inclusion and exclusion criteria after&#xD;
      MRI-examination. Randomization will be in random permuted blocks of 6 at a ratio of 1:1. The&#xD;
      randomization will be according to a computer generated randomization sequence. After&#xD;
      patients have signed informed consent and fulfill inclusion without exclusion criteria after&#xD;
      the initial magnetic resonance imaging they will be allocated to an intervention by&#xD;
      consecutive opening of sealed opaque envelopes containing the randomization code.&#xD;
&#xD;
      Blinding&#xD;
&#xD;
      Patients and investigators will not be blinded. The MRI will be performed and evaluated by a&#xD;
      blinded radiologist.&#xD;
&#xD;
      Method&#xD;
&#xD;
      Pre randomization evaluation After having signed informed consent but before randomization&#xD;
      patients will undergo MRI of the uterus. Patients with endometriosis or a clinically&#xD;
      significant presence of uterine fibroids (myomas&gt;3cm) will be excluded.&#xD;
&#xD;
      All women included in the study after MRI examination will fill in a PBAC evaluation during&#xD;
      the menses preceding treatment. Women will fill a VNRS for maximal pain during 1 month prior&#xD;
      to treatment. In addition a full blood panel will be evaluated.&#xD;
&#xD;
      As for uterine artery embolization no pathologist report will be performed before any&#xD;
      treatment.&#xD;
&#xD;
      Microwave ablation Microwave ablation will be performed percutaneously or vaginally using a&#xD;
      Covidien Emprint microwave ablation system with a 30-80 Watts effect in 14-16 gauge needle&#xD;
      with a ceramic tip using computer tomography with fusion technique or ultrasound for&#xD;
      adenomyosis imaging and needle guidance. After identification of the needle path with CT or&#xD;
      peroperative ultrasound a small skin incision using a scalpel will made for the needle entry&#xD;
      in the case of percutaneous treatment. No incision will be made if treatment is given&#xD;
      vaginally. When needed to optimize the needle path in order not to damage adjacent organs,&#xD;
      artificial ascites (approx 500mL Ringer-acetate) will be created using a thin syringe through&#xD;
      the abdominal wall. The ablation zone of a 70W needle is estimated to be 4x3x3 cm after 300s&#xD;
      or 5x4x4 cm after 600s. Patients will be given intravenous anesthesia with spontaneous&#xD;
      breathing or general anesthesia during treatment to minimize movement during ablation.&#xD;
&#xD;
      Uterine artery embolization Embolization will be performed in conscious women with an&#xD;
      epidural catheter or patient controlled analgesia for pain relief. A catheter will be&#xD;
      inserted in the femoral artery to access the uterine artery during x-ray monitoring and&#xD;
      during administration of contrast to visualize the adenomyotic tissue and its supporting&#xD;
      arterial supply. When the supporting arterial branch has been identified polyvinyl alcohol&#xD;
      particles are released into the bloodstream. These particles cause a thrombosis in the&#xD;
      vessel.&#xD;
&#xD;
      Evaluation post treatment Women will estimate VNRS maximum postoperative pain day of surgery&#xD;
      and the following 7 days. In addition, they will note how many days passed before all pain&#xD;
      subsided, use of pain medication will be noted and period until resuming normal daily&#xD;
      activities. The period of hospitalization will be noted.&#xD;
&#xD;
      Menstrual blood loss (PBAC) will be noted the first menstruation, menstruation number 3 and 5&#xD;
      post treatment. PBAC is a validated instrument for menstrual blood loss quantification.&#xD;
      UFS-QOL is a validated instrument for women with uterine fibroids, but is commonly used also&#xD;
      in trials regarding adenomyosis, and will be evaluated 6 months post treatment.&#xD;
&#xD;
      Follow-up visits will be after 1-2 menstruation at approximately 2 months and at 6 months&#xD;
      post-treatment.&#xD;
&#xD;
      At follow up visit 2 months (+/-2 weeks) and 6 months (+/-2 weeks) post treatment&#xD;
      acceptability will be assessed as overall satisfaction of treatment on a scale from 1-7 and&#xD;
      if the woman would recommend the treatment to a friend. At the follow up visit at 6 months&#xD;
      hemoglobin, cancer antigen 125 (CA-125), Anti-MÃ¼llerian Hormone (AMH), and prolactine (PRL)&#xD;
      will be measured. AMH estimates the effect of the treatment on the ovarian reserve. CA-125&#xD;
      and PRL have been used to evaluate pathophysiological changes in adenomyosis. These will be&#xD;
      compared to levels taken on the day of the operative procedure. A uterine biopsy will also be&#xD;
      performed.&#xD;
&#xD;
      A new MRI scan will be performed 6 months post treatment (+/-21 days). Women will then be&#xD;
      asked to participate in a long-term follow up (&gt;12 months) with evaluation of recurrence of&#xD;
      symptoms, with clinical controls (gynecological exams and TVUS) and using PBAC and UFS-QOL&#xD;
      yearly until retraction of consent.&#xD;
&#xD;
      Clinical significance&#xD;
&#xD;
      Adenomyosis is a benign condition but have a significant impact on the lives of women, and&#xD;
      the condition is not well studied. Reports have suggested adenomyosis in approximately 40% of&#xD;
      patients undergoing hysterectomy. Women with adenomyosis are much more likely to report on&#xD;
      symptoms as dysmenhorrea, heavy menstrual bleeding, infertility and chronic pelvic pain. As&#xD;
      hysterectomy is a highly invasive procedure with costs for women in terms of absence from&#xD;
      work and short and long term complications, finding new minimally invasive and&#xD;
      uterine-sparing treatments would be beneficial for affected women.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">February 2020</start_date>
  <completion_date type="Anticipated">February 2022</completion_date>
  <primary_completion_date type="Anticipated">August 2021</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>1. Symptom improvement 6 months post treatment (+/-21 days) compared to pre treatment, evaluated by UFS-QOL</measure>
    <time_frame>6 months</time_frame>
    <description>Symptom improvement evaluated by the validated questionnaire UFS-QOL, which is subdivided into Symptom Severity Scale (0-100, where higher number represent worsened symptoms) and HRQL items (concern, activities, energy/mood, control, self-consciousness and sexual function, range 0-100 where higher numbers represent better Quality of Life)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Symptom improvement 6 months post treatment (+/-21 days) compared to pre treatment, evaluated by PBAC (pictorial blood loss assessment chart)</measure>
    <time_frame>6 months</time_frame>
    <description>Symptom improvement in regard to menstrual blood loss, PBAC ranges from 0-&gt;4000 and cut-off for the diagnose of Heavy Menstrual Bleeding is normally PBAC&gt;100</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Symptom improvement 6 months post treatment (+/-21 days) compared to pre treatment, evaluated by</measure>
    <time_frame>6 months</time_frame>
    <description>Symptom improvement in regard to menstrual pain, evaluated by VNRS (0-10, recorded each day of the menstrual period, where 0 is no pain and 10 worst possible pain)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Reduction of adenomyosis by imaging</measure>
    <time_frame>6 months</time_frame>
    <description>Reduction of uterus volume/adenomyosis affected areas, measured as lesional size (in mm or cm) measured by Transvaginal ultrasound and/or MRI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospitalization</measure>
    <time_frame>Up to 8 weeks post treatment</time_frame>
    <description>How long time (in days) the patient needed postoperative care in the ward, identified by the patients Medical chart</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sick leave</measure>
    <time_frame>Up to 8 weeks post treatment</time_frame>
    <description>How many Days until the patient resumed normal working hours</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain medication</measure>
    <time_frame>Up to 8 weeks post treatment</time_frame>
    <description>How much and what type of pain medication the patient needed post operatively</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acceptability</measure>
    <time_frame>2 months and 6 months post treatment</time_frame>
    <description>Patients description wether they would recommend the treatment to a friend, measured by a 7-point Likert scale (1-7, where higher number represents a greater acceptability)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Adenomyosis</condition>
  <arm_group>
    <arm_group_label>Microwave treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Percutaneous or vaginal application of microwave antenna with microwave treatment for adenomyosis</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Uterine artery embolization; percutaneous application of a catheter into the femoral artery or branches thereof</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Microwave treatment via needle antenna</intervention_name>
    <description>Microwave treatment via needle antenna, (Emprint Covidien microwave ablation system) either percutaneous or vaginally administrated</description>
    <arm_group_label>Microwave treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Embolization of uterine artery or branches thereof (routine treatment where polyvinyl alcohol particles are released into the predefined bloodstream)</intervention_name>
    <description>Embolization via percutaneous catheter</description>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy women aged 30-55 with symptomatic adenomyosis&#xD;
&#xD;
          -  Premenopausal&#xD;
&#xD;
          -  Adenomyosis diagnosted by TVUS and MRI&#xD;
&#xD;
          -  Willing to comply with protocol&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Current or future childwish&#xD;
&#xD;
          -  Body Mass Index &gt;35&#xD;
&#xD;
          -  Treatment with anticoagulant/bleeding disorder&#xD;
&#xD;
          -  Visible myomas &gt;3cm or visible endometriosis on UL/MRI&#xD;
&#xD;
          -  Contraindication for UAE or general anesthesia&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Helena Kopp Kallner, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Karolinska Institutet</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Klara Hasselrot, MD PhD</last_name>
    <phone>+46812358927</phone>
    <email>klara.hasselrot@sll.se</email>
  </overall_contact>
  <reference>
    <citation>Struble J, Reid S, Bedaiwy MA. Adenomyosis: A Clinical Review of a Challenging Gynecologic Condition. J Minim Invasive Gynecol. 2016 Feb 1;23(2):164-85. doi: 10.1016/j.jmig.2015.09.018. Epub 2015 Sep 30. Review.</citation>
    <PMID>26427702</PMID>
  </reference>
  <reference>
    <citation>Pinzauti S, Lazzeri L, Tosti C, Centini G, Orlandini C, Luisi S, Zupi E, Exacoustos C, Petraglia F. Transvaginal sonographic features of diffuse adenomyosis in 18-30-year-old nulligravid women without endometriosis: association with symptoms. Ultrasound Obstet Gynecol. 2015 Dec;46(6):730-6. doi: 10.1002/uog.14834.</citation>
    <PMID>25728241</PMID>
  </reference>
  <reference>
    <citation>Dueholm M. Uterine adenomyosis and infertility, review of reproductive outcome after in vitro fertilization and surgery. Acta Obstet Gynecol Scand. 2017 Jun;96(6):715-726. doi: 10.1111/aogs.13158. Review.</citation>
    <PMID>28556124</PMID>
  </reference>
  <reference>
    <citation>Li X, Liu X, Guo SW. Clinical profiles of 710 premenopausal women with adenomyosis who underwent hysterectomy. J Obstet Gynaecol Res. 2014 Feb;40(2):485-94. doi: 10.1111/jog.12211. Epub 2013 Oct 22.</citation>
    <PMID>24148010</PMID>
  </reference>
  <reference>
    <citation>Van den Bosch T, Van Schoubroeck D. Ultrasound diagnosis of endometriosis and adenomyosis: State of the art. Best Pract Res Clin Obstet Gynaecol. 2018 Aug;51:16-24. doi: 10.1016/j.bpobgyn.2018.01.013. Epub 2018 Feb 14. Review.</citation>
    <PMID>29506961</PMID>
  </reference>
  <reference>
    <citation>Sheng J, Zhang WY, Zhang JP, Lu D. The LNG-IUS study on adenomyosis: a 3-year follow-up study on the efficacy and side effects of the use of levonorgestrel intrauterine system for the treatment of dysmenorrhea associated with adenomyosis. Contraception. 2009 Mar;79(3):189-93. doi: 10.1016/j.contraception.2008.11.004. Epub 2008 Dec 11.</citation>
    <PMID>19185671</PMID>
  </reference>
  <reference>
    <citation>de Bruijn AM, Smink M, Lohle PNM, Huirne JAF, Twisk JWR, Wong C, Schoonmade L, Hehenkamp WJK. Uterine Artery Embolization for the Treatment of Adenomyosis: A Systematic Review and Meta-Analysis. J Vasc Interv Radiol. 2017 Dec;28(12):1629-1642.e1. doi: 10.1016/j.jvir.2017.07.034. Epub 2017 Oct 9. Review.</citation>
    <PMID>29032946</PMID>
  </reference>
  <reference>
    <citation>de Bruijn AM, Lohle PN, Huirne JA, de Vries J, Twisk M; QUESTA-Trial Group, Hehenkamp WJ. Uterine Artery Embolization Versus Hysterectomy in the Treatment of Symptomatic Adenomyosis: Protocol for the Randomized QUESTA Trial. JMIR Res Protoc. 2018 Mar 1;7(3):e47. doi: 10.2196/resprot.8512.</citation>
    <PMID>29496654</PMID>
  </reference>
  <reference>
    <citation>Guo Q, Xu F, Ding Z, Li P, Wang X, Gao B. High intensity focused ultrasound treatment of adenomyosis: a comparative study. Int J Hyperthermia. 2018;35(1):505-509. doi: 10.1080/02656736.2018.1509238. Epub 2018 Oct 11.</citation>
    <PMID>30306813</PMID>
  </reference>
  <reference>
    <citation>Hai N, Zhang J, Xu R, Han ZY, Liu FY. Percutaneous microwave ablation with artificial ascites for symptomatic uterine adenomyosis: initial experience. Int J Hyperthermia. 2017 Sep;33(6):646-652. doi: 10.1080/02656736.2017.1285444. Epub 2017 Feb 15.</citation>
    <PMID>28118773</PMID>
  </reference>
  <reference>
    <citation>Xu RF, Zhang J, Han ZY, Zhang BS, Liu H, Li XM, Ge HL, Dong XJ. Variables associated with vaginal discharge after ultrasound-guided percutaneous microwave ablation for adenomyosis. Int J Hyperthermia. 2016 Aug;32(5):504-10. doi: 10.3109/02656736.2016.1150523. Epub 2016 Apr 18.</citation>
    <PMID>27087631</PMID>
  </reference>
  <reference>
    <citation>Yang Y, Zhang J, Han ZY, Ma X, Hao YL, Xu CT, Xu RF, Zhang BS. Ultrasound-guided percutaneous microwave ablation for adenomyosis: efficacy of treatment and effect on ovarian function. Sci Rep. 2015 May 5;5:10034. doi: 10.1038/srep10034.</citation>
    <PMID>25942631</PMID>
  </reference>
  <reference>
    <citation>Xia M, Jing Z, Zhi-Yu H, Jian-Ming C, Hong-Yu Z, Rui-Fang X, Yu Y, Yan-Li H, Bao-Wei D. Feasibility study on energy prediction of microwave ablation upon uterine adenomyosis and leiomyomas by MRI. Br J Radiol. 2014 Aug;87(1040):20130770. doi: 10.1259/bjr.20130770. Epub 2014 Jun 20.</citation>
    <PMID>24947033</PMID>
  </reference>
  <reference>
    <citation>Zhang J, Han ZY, Feng L, Wang F, Hu DM, Wen B, Li ZC. [Ultrasound-guided percutaneous microwave ablation in the treatment of diffuse adenomyosis]. Zhonghua Yi Xue Za Zhi. 2011 Oct 25;91(39):2749-52. Chinese.</citation>
    <PMID>22322052</PMID>
  </reference>
  <reference>
    <citation>Reid PC, Coker A, Coltart R. Assessment of menstrual blood loss using a pictorial chart: a validation study. BJOG. 2000 Mar;107(3):320-2.</citation>
    <PMID>10740326</PMID>
  </reference>
  <reference>
    <citation>Spies JB, Coyne K, Guaou Guaou N, Boyle D, Skyrnarz-Murphy K, Gonzalves SM. The UFS-QOL, a new disease-specific symptom and health-related quality of life questionnaire for leiomyomata. Obstet Gynecol. 2002 Feb;99(2):290-300.</citation>
    <PMID>11814511</PMID>
  </reference>
  <reference>
    <citation>Harding G, Coyne KS, Thompson CL, Spies JB. The responsiveness of the uterine fibroid symptom and health-related quality of life questionnaire (UFS-QOL). Health Qual Life Outcomes. 2008 Nov 12;6:99. doi: 10.1186/1477-7525-6-99.</citation>
    <PMID>19014505</PMID>
  </reference>
  <reference>
    <citation>Coyne KS, Margolis MK, Murphy J, Spies J. Validation of the UFS-QOL-hysterectomy questionnaire: modifying an existing measure for comparative effectiveness research. Value Health. 2012 Jul-Aug;15(5):674-9. doi: 10.1016/j.jval.2012.03.1387. Epub 2012 Jun 8.</citation>
    <PMID>22867776</PMID>
  </reference>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>December 16, 2019</study_first_submitted>
  <study_first_submitted_qc>December 20, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 23, 2019</study_first_posted>
  <last_update_submitted>December 20, 2019</last_update_submitted>
  <last_update_submitted_qc>December 20, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 23, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Karolinska Institutet</investigator_affiliation>
    <investigator_full_name>Helena Kopp Kallner</investigator_full_name>
    <investigator_title>Senior Consultant, PhD</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenomyosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

